James Gordon CFA
Stock Analyst at Barclays
(3.58)
# 2,290
Out of 4,698 analysts
151
Total ratings
67.7%
Success rate
6.9%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 125.00 | CHF 131.32 | -4.81% | 10 | Sep 2, 2026 | |
| LON: GSK GSK plc | Maintained: Sell | 1,900p | 1,867p | +1.79% | 27 | Sep 1, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,500p | 12,146p | +35.85% | 15 | Aug 18, 2026 | |
| LON: 0QW0 argenx SE | Reiterated: Buy | €980.00 → €1,000 | €911.30 | +9.73% | 16 | Aug 18, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €22.00 | €25.04 | -12.14% | 2 | Aug 11, 2026 | |
| LON: 0MGB Genmab A/S | Reiterated: Buy | kr 2,500 | kr 2,197 | +13.79% | 8 | Aug 10, 2026 | |
| GMAB Genmab | Maintained: Buy | n/a | $34.41 | - | 1 | Aug 7, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 300.00 → kr 310.00 | kr 301.55 | +2.80% | 17 | Aug 6, 2026 | |
| SWX: SDZ Sandoz Group AG | Maintained: Buy | CHF 81.00 | CHF 70.36 | +15.12% | 8 | Aug 6, 2026 | |
| ARGX argenx SE | Maintained: Buy | $950 | $1,053.46 | -9.82% | 1 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 200.00 → CHF 210.00 | CHF 162.85 | +28.95% | 23 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 530.00 | kr 460.00 | +15.22% | 1 | Jul 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | 1,350p | 1,605p | -15.89% | 3 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 410.00 | CHF 356.50 | +15.01% | 13 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €85.00 | €76.27 | +11.45% | 6 | Apr 23, 2026 |
Novartis AG
Sep 2, 2026
Maintained: Hold
Price Target: CHF 125.00
Current: CHF 131.32
Upside: -4.81%
GSK plc
Sep 1, 2026
Maintained: Sell
Price Target: 1,900p
Current: 1,867p
Upside: +1.79%
AstraZeneca PLC
Aug 18, 2026
Maintained: Buy
Price Target: 16,500p
Current: 12,146p
Upside: +35.85%
argenx SE
Aug 18, 2026
Reiterated: Buy
Price Target: €980.00 → €1,000
Current: €911.30
Upside: +9.73%
Lakefront Biotherapeutics NV
Aug 11, 2026
Maintained: Sell
Price Target: €22.00
Current: €25.04
Upside: -12.14%
Genmab A/S
Aug 10, 2026
Reiterated: Buy
Price Target: kr 2,500
Current: kr 2,197
Upside: +13.79%
Genmab
Aug 7, 2026
Maintained: Buy
Price Target: n/a
Current: $34.41
Upside: -
Novo Nordisk A/S
Aug 6, 2026
Maintained: Hold
Price Target: kr 300.00 → kr 310.00
Current: kr 301.55
Upside: +2.80%
Sandoz Group AG
Aug 6, 2026
Maintained: Buy
Price Target: CHF 81.00
Current: CHF 70.36
Upside: +15.12%
argenx SE
Jul 24, 2026
Maintained: Buy
Price Target: $950
Current: $1,053.46
Upside: -9.82%
Jul 24, 2026
Reiterated: Buy
Price Target: CHF 200.00 → CHF 210.00
Current: CHF 162.85
Upside: +28.95%
Jul 3, 2026
Maintained: Buy
Price Target: kr 530.00
Current: kr 460.00
Upside: +15.22%
Jun 23, 2026
Maintained: Sell
Price Target: 1,350p
Current: 1,605p
Upside: -15.89%
May 26, 2026
Maintained: Buy
Price Target: CHF 410.00
Current: CHF 356.50
Upside: +15.01%
Apr 23, 2026
Maintained: Hold
Price Target: €85.00
Current: €76.27
Upside: +11.45%